N/A N=59 The Step Home Trial: Utilising Physical Activity Data in the Acute Post-operative Setting
Surgery · Enhanced Recovery · Technology
Primary: Total Activity Pre-op — 177; 154; 186 minutes of activity per 24 hour period
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=64 Tracheal Intubation With the Rigid Tube for Laryngoscopy- a New Method
Intubation;Difficult
Primary: Time to Tracheal Intubation With the Rigid Tube — 50.5 seconds
N/A N=53 QP ExCELs: MultiPole Pacing (MPP) Sub-Study
Heart Failure
Primary: Cardiac Resynchronization Therapy (CRT) Responder Status With the MPP Feature — 16; 23; 6 Participants — p=<0.0001
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=101 Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
Pulmonary Fibrosis
Primary: Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 52 — -0.5; 4.1 Percentage of predicted FVC — p=0.505
N/A N=23 Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery
Skull Base Neoplasms · Skull Neoplasms · Bone Neoplasm
Primary: ICG Fluorescence Ratio — 0.92; 0.82 Ratio
N/A N=11 Exercise Training in Heart Failure: Changes in Cardiac Structure and Function
Heart Failure
Primary: Change in Left Ventricular Systolic Function. — .82; -1.90 percent LVEF — p=.14
Phase 2 N=399 A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c — -0.58; -0.57; -0.66 HbA1C % — p=<0.001
N/A N=200 Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis · Secondary Progressive Multiple Sclerosis
Primary: Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy. — 178 Participants
Phase 1 N=9 A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Acute Myeloid Leukemia
Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants
N/A N=15 Evaluation of Clinical Outcomes of Pulse Widths in Spinal Cord Stimulation
Back Pain · Pain
Primary: Effect of Pulse Widths on Pain Clinical Outcomes — 15; 0 Participants
Phase 3 N=144 Targeted Retreatment of COPD Exacerbations
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Time to the Next COPD Exacerbation — 72; 58 days — p=0.764
Phase 4 N=103 Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control
Hypertension
Primary: Changes in 24 Hour Systolic Blood Pressure — 129.65; 129.75 mm Hg
N/A N=543 Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)
Kidney Disease, End-Stage
Primary: Symptoms - Trajectory of Change — 77.2; 76.2 score on a scale — p=0.30
Phase 2 N=13 Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Kaposi's Sarcoma
Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants